Vorasidenib

Introduction Overview

Generic Name

vorasidenib

Brand Name

Voranigo

Dosage Form

tablets (20 mg, 40 mg)

Drug Class

Miscellaneous antineoplastics; isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor

Pharmacokinetics

Absorption:
Vorasidenib is administered orally as tablets and exhibits well-absorbed pharmacokinetics with once-daily dosing. The absorption kinetics support sufficient systemic exposure to allow central nervous system penetration, which is critical given its target brain tumors. Food does not significantly impact the absorption, permitting administration with or without meals. The precise bioavailability data have been elucidated in early phase trials, showing consistent plasma levels suitable for sustained target engagement.

Distribution:
Vorasidenib demonstrates effective penetration across the blood-brain barrier, a critical pharmacokinetic property for agents targeting central nervous system malignancies such as gliomas. The distribution profile indicates adequate concentration in brain tissue, notably within tumor microenvironments expressing mutant IDH1/IDH2 enzymes. Plasma protein binding parameters and volume of distribution data suggest moderate to extensive tissue distribution beyond plasma, supporting its therapeutic efficacy in brain tumors.

Metabolism:
Vorasidenib metabolism involves hepatic biotransformation primarily mediated by cytochrome P450 enzymes, particularly CYP3A4 isoform, as suggested by in vitro and clinical drug-drug interaction studies. Metabolic pathways reduce active drug concentrations while leading to potentially inactive metabolites. The effect of enzyme inducers or inhibitors on vorasidenib plasma levels has implications for drug interactions and necessitates careful co-administration considerations.

Elimination:
The elimination of vorasidenib occurs predominantly through hepatobiliary routes with fecal excretion as a major pathway. Renal clearance plays a minor role given the drug's metabolic profile. The elimination half-life supports a once-daily dosing regimen, with sufficient plasma half-life to maintain therapeutic levels. Impaired hepatic function may significantly alter elimination kinetics and may require dose adjustment in affected patients. Clinical pharmacokinetic studies confirm steady-state concentration attainment and the tolerability profile aligning with elimination characteristics.

Dosage Forms

Available Dosage Forms:
- Oral tablets available in 20 mg and 40 mg strengths.

Dosages for Adults and Adolescents:
- Adults and pediatric patients aged 12 years and older weighing ≥40 kg: 40 mg orally once daily.
- Pediatric patients aged 12 years and older weighing <40 kg: 20 mg orally once daily.
- Treatment continues until disease progression or unacceptable toxicity occurs.

Specific Patient Populations:
- Pediatric patients (age ≥12 years) are dosed based on weight category as described.
- No specific dosage adjustment has been detailed for renal or hepatic impairment; however, caution and monitoring are advised due to metabolism and elimination profiles.
- Patients are instructed to swallow tablets whole without crushing, splitting, or chewing, ensuring proper release and absorption.
- The drug can be taken with or without food, allowing flexibility in administration.
- Adherence to once-daily dosing at the same time each day is essential for consistent therapeutic effect.
- Missed doses guidelines specify taking the dose within 6 hours or skipping if beyond to maintain safety.

Clinical Guidelines:
- For optimal effect, dosing is continuous post-surgery, including after biopsy, subtotal, or gross total resection, targeting residual IDH1/IDH2-mutant astrocytoma and oligodendroglioma cells.
- Regular monitoring for liver function and side effects is critical during therapy to guide dosing continuation or modification.

Mechanism Of Action

Vorasidenib is a targeted small molecule inhibitor specifically designed to bind and inhibit the mutated forms of isocitrate dehydrogenase enzymes IDH1 and IDH2. These mutated enzymes acquire neomorphic activity, converting isocitrate to the oncometabolite 2-hydroxyglutarate (2-HG), which is implicated in tumorigenesis through epigenetic dysregulation.

By selectively inhibiting mutated IDH1 and IDH2 enzymes, vorasidenib reduces intracellular levels of 2-HG, thereby reversing the aberrant epigenetic modifications that promote malignant cell proliferation and block cellular differentiation. This restoration of near-normal cellular differentiation contributes to slowing tumor growth and progression in IDH-mutant gliomas.

Cellular pathways impacted by vorasidenib include epigenetic regulation via modulation of histone and DNA methylation patterns affected by excessive 2-HG. This biochemical interaction influences gene expression profiles, promoting differentiation and reducing the malignant phenotype of tumor cells.

Clinically, vorasidenib’s mechanism has been validated in Phase 3 INDIGO trials demonstrating prolonged progression-free survival and tumor volume reduction in patients with low-grade IDH-mutant gliomas. Its dual inhibition of both IDH1 and IDH2 mutations distinguishes it from agents targeting only one isoform, potentially broadening the therapeutic applicability. Preclinical and clinical studies support its targeted action with a favorable safety profile compared to traditional cytotoxic chemotherapies.

Pharmacological Actions

Selective inhibition of mutated IDH1 and IDH2 enzymes.
Reduction of oncometabolite 2-hydroxyglutarate (2-HG) production.
Restoration of normal epigenetic regulation and cellular differentiation.
Antineoplastic activity against IDH-mutant astrocytoma and oligodendroglioma cells.
Crosses the blood-brain barrier to target central nervous system tumors.
Oral bioavailability supporting convenient once-daily dosing.
Demonstrated tumor volume stabilization and shrinkage in clinical trials.
Potential to delay progression of low-grade gliomas with mutant IDH enzymes.
Modulation of histone and DNA methylation by altering 2-HG mediated pathways.
Favorable safety profile with manageable adverse effects in clinical use.
Targeted mechanism reducing non-specific cytotoxicity compared to conventional chemotherapy.
Dose-dependent pharmacokinetics facilitating personalized dosing in pediatric populations.
Pharmacodynamic effects correlated with reduction in 2-HG biomarker levels.
Minimal impact on wild-type IDH enzymes preserving normal cellular metabolism.
Potential synergy with other targeted or immunotherapeutic agents under investigation.

Therapeutic Or Clinical Uses

Treatment of Grade 2 astrocytoma tumors harboring IDH1 or IDH2 mutations.
Management of Grade 2 oligodendroglioma with susceptible IDH1 or IDH2 mutations.
Use as adjuvant therapy post-surgical biopsy, sub-total resection, or gross total resection.
Extended progression-free survival in patients with IDH-mutant low-grade gliomas.
Reduction of tumor growth and stabilization of tumor volume in targeted brain cancers.
Treatment option for patients aged 12 years and older with relevant mutations.
Alternative to traditional chemotherapy for IDH-mutant glioma patients.
Potential delaying agent for malignant transformation or progression in low-grade gliomas.
Indicated in patients following molecular characterization confirming IDH mutation status.
Expanding therapeutic landscape for molecularly defined CNS tumors.
Supportive therapy combined with surgical and radiotherapeutic interventions.
Investigational use in IDH-mutant glioma clinical trial settings prior to approval.
Management of recurrent or residual gliomas with IDH mutation after initial therapy.
Potential application in other IDH mutation-driven malignancies under active research.
Adjunct to symptomatic management in central nervous system tumor patients.

Side Or Adverse Effects

Fatigue or tiredness occurring in approximately 37% of patients.
Increased incidence of COVID-19 infection in 33% of treated individuals, possibly reflecting immunomodulation.
Muscle and joint pain reported by 26% of patients during therapy.
Gastrointestinal disturbances including diarrhea (25%) and constipation (13%).
Seizures observed in 16% of patients, requiring monitoring especially in CNS tumor context.
Abdominal pain reported in about 13% of cases.
Nausea and decreased appetite noted, impacting nutritional status.
Laboratory abnormalities including increased liver enzymes (ALT, AST, GGT) and decreased neutrophils in some patients.
Serious liver toxicity presenting as jaundice, dark urine, upper right abdominal pain, and extreme fatigue.
Potential fertility impairment in both males and females requiring counseling.
Risk of hepatic function deterioration necessitating regular liver function tests.
Possible interplay with hormonal contraceptives reducing their effectiveness.
Other less common side effects include rash, headache, and metabolic abnormalities.
Risk of severe adverse events increases with prolonged treatment or coexisting organ dysfunction.
Patients should report early signs of liver dysfunction or neurological changes promptly.

Precautions

Perform baseline and regular monitoring of liver function tests due to risk of hepatotoxicity.
Monitor for new or worsening seizure activity in patients with CNS tumors.
Assess renal function and be cautious in patients with kidney impairment or on dialysis.
Inquire about tobacco use as smoking may impact drug metabolism and efficacy.
Pregnancy testing is required in women of childbearing potential before and during therapy.
Use effective nonhormonal contraception during treatment and for three months after discontinuation.
Male patients should use effective contraception to avoid potential teratogenic risks.
Advise patients not to crush, chew, or split tablets to ensure proper drug release.
Counsel patients on potential decrease in effectiveness of hormonal contraceptives while on therapy.
Educate patients to report symptoms of liver toxicity such as jaundice or abdominal pain immediately.
Adjust dosing or discontinue treatment based on severity of adverse events or toxicities.
Consider careful assessment of concomitant medications to avoid interactions.
Use with caution in patients with pre-existing liver or kidney disease.
Inform patients about the importance of adherence to once-daily dosing regimen.
Regular clinical assessment to evaluate for signs of disease progression or toxicity.

Warnings

Potential for serious liver injury including cholestatic and hepatocellular damage.
Necessity of frequent liver function monitoring to detect subclinical hepatotoxicity early.
Risk of teratogenicity and harm to unborn fetus; contraindicated in pregnancy.
Reduced efficacy of hormonal contraceptives leading to unintended pregnancies.
Patients with pre-existing seizure disorders may experience increased seizure frequency.
Possibility of immunosuppression or increased susceptibility to infections such as COVID-19.
Dose modifications or discontinuation may be required with severe adverse reactions.
Not recommended for use in pediatric patients under 12 years due to lack of data.
Warn patients against abrupt cessation; adherence is critical to prevent disease progression.
Use caution when combining with strong CYP3A4 inhibitors or inducers due to interaction risk.
May impair fertility in both male and female patients; discuss fertility preservation options.
Risk of potential cumulative toxicity with long-term treatment.
Advise patients to avoid activities requiring mental alertness if they experience fatigue or CNS effects.
Pregnancy testing and effective contraception mandatory for females during and post-therapy.
Hepatic impairment may necessitate closer monitoring and possible dose adjustment.

Contraindication

Known hypersensitivity to vorasidenib or any components of the formulation.
Pregnancy due to potential teratogenic effects.
Severe hepatic impairment not adequately monitored or managed.
Patients unable to adhere to regular liver function testing and monitoring protocols.
Concurrent use with drugs contraindicated due to significant CYP3A4-mediated interactions without possibility of adjustment.
Use in pediatric patients younger than 12 years due to insufficient safety and efficacy data.
Conditions where the oral administration of tablets is contraindicated (e.g., inability to swallow tablets).
Presence of active uncontrolled infections that may exacerbate toxicity.
Severe neutropenia or bone marrow failure uncorrected prior to initiation.
Concurrent participation in another investigational drug trial without clear rationale.
History of severe adverse reactions to IDH inhibitors or similar targeted therapies.
Patients with compromised fertility seeking conception without prior counseling.
Allergic reactions to inactive tablet ingredients such as lactose or hypromellose.
Patients with unstable CNS conditions where seizure risk cannot be managed.
Use is contraindicated if diagnosis does not confirm IDH1 or IDH2 mutation positivity.

Drug Interactions

Potential interaction with CYP3A4 inhibitors or inducers affecting vorasidenib metabolism and plasma levels.
Reduced effectiveness of hormonal contraceptives when coadministered; alternative contraception recommended.
Co-administration with immunosuppressive agents may increase infection risk.
Avoid concomitant use with strong CYP3A4 inducers such as rifampin or carbamazepine.
Careful monitoring suggested when used with other hepatotoxic drugs to avoid additive liver injury.
May interact with certain antiepileptic drugs potentially altering seizure threshold.
Potential pharmacodynamic interactions with other antineoplastic agents leading to increased toxicity.
Patients should inform healthcare providers of all prescription, over-the-counter, and herbal supplements.
Drugs altering gastric pH or motility are unlikely to affect absorption significantly but should be monitored.
Concomitant use with other CNS-active agents requires vigilance for additive CNS adverse effects.
Possible alterations in vorasidenib clearance with drugs affecting hepatic enzyme function.
Caution with concomitant nephrotoxic drugs considering patient’s renal function status.
Interactions with anticoagulants or antiplatelet medications have not been fully characterized but warrant monitoring.
Avoid combination with strong CYP3A4 inhibitors without monitoring or dose adjustment.
Drug interaction profiles necessitate comprehensive medication review before starting therapy.

Preparations Of The Drug

Vorasidenib is formulated as oral tablets available in 20 mg and 40 mg strengths.
Tablets contain active ingredient vorasidenib and inactive ingredients such as croscarmellose sodium, magnesium stearate, microcrystalline cellulose, silicified microcrystalline cellulose, and sodium lauryl sulfate.
Tablet coating consists of hypromellose, lactose monohydrate, macrogol, titanium dioxide aimed at stability and release control.
Black printing ink on tablets contains black iron oxide, hypromellose, and propylene glycol to identify the tablet strength and branding.
Supplied in bottles with desiccant canisters to maintain tablet integrity and prevent moisture exposure; desiccant should not be ingested.
Packaging includes child-resistant caps to enhance safety in home storage.
Intended for oral use only with instructions to swallow tablets whole without crushing or chewing to maintain proper bioavailability.
Stored at controlled room temperature between 20°C and 25°C (68°F – 77°F) to preserve stability.
Manufactured and distributed by Servier Pharmaceuticals LLC, ensuring compliance with regulatory standards.
Available as a prescription-only medication with FDA approval specifically for IDH1/2-mutant gliomas.
Distributed with detailed prescribing information and patient medication guides to support safe use.
Packaging includes lot number and expiration date to ensure quality control.
Intended as a once-daily oral therapy for long-term management until disease progression or unacceptable toxicity.
Handling by healthcare professionals should observe safety and storage protocols.
Not available in injectable, liquid, or alternative formulations as of current labeling.